To counter the growing public health problem posed by antimicrobial resistance and the diminishing arsenal of effective therapies to combat those pathogens, governments are implementing regulatory policies and funding programs designed to create an environment that will encourage biopharmas to commit research and development resources toward the development of novel antibiotics and antifungals.